Browse by author
Lookup NU author(s): Dr Thomas Huegle, Professor Jaap Van Laar
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Immunoablative therapy and hematopoietic stem cell transplantation (HSCT) is an intensive treatment modality aimed at 'resetting' the dysregulated immune system of a patient with immunoablative therapy and allow outgrowth of a nonautogressive immune system from reinfused hematopoietic stem cells, either from the patient (autologous HSCT) or a healthy donor ( allogeneic HSCT). HSCT has been shown to induce profound alterations of the immune system affecting B and T cells, monocytes, and natural killer and dendritic cells, resulting in elimination of autoantibody-producing plasma cells and in induction of regulatory T cells. Most of the available data have been collected through retrospective cohort analyses of autologous HSCT, case series, and translational studies in patients with refractory autoimmune diseases. Long-term and marked improvements of disease activity have been observed, notably in systemic sclerosis, systemic lupus erythematosus, and juvenile idiopathic arthritis, and treatment-related morbidity and mortality have improved due to better patient selection and modifications of transplant regimens. Treatment-related mortality has decreased to approximately 7%. Prospective, randomised, controlled clinical trials are ongoing or planned in systemic sclerosis, systemic lupus erythematosus, and several nonrheumatological conditions.
Author(s): Hugle T, van Laar JM
Publication type: Article
Publication status: Published
Journal: Arthritis Research & Therapy
Year: 2008
Volume: 10
Issue: 5
Pages: 217
ISSN (print): 1478-6354
ISSN (electronic): 1478-6362
URL: http://dx.doi.org/10.1186/ar2486
DOI: 10.1186/ar2486
Altmetrics provided by Altmetric
